

#### Medical & Clinical Research

#### Tumors of lung and pleura

#### **Daniel Benharroch\***

Department of Pathology, Soroka University Medical Center, Ben Gurion University of the Negev, Beer Sheva, Israel.


\*Corresponding author Daniel Benharroch, Department of Pathology, Soroka University Medical Center, Ben Gurion University of the Negev, Beer Sheva, Israel.

Submitted: 28 Aug 2022; Accepted: 30 Aug 2022; Published: 01 Sep 2022

Citation: Daniel Benharroch (2022) Tumors of lung and pleura. Medical & Clinical Research 7(9):01.

Copyright: ©2022: Daniel Benharroch. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### **TUMORS OF LUNG AND PLEURA**



### **Primary Tumors of Lung**

- Carcinoma (90%-95%)
- Bronchial carcinoid (5%)
- Mesenchymal and other miscellaneous tumors (2%-5%)

## LUNG CANCER

Near 1/3 mortality from cancer
84% will die within 5 years
Most will be diagnosed after age 40 (98%)
Cigarette smoking – main risk factor (87%)
75% are centrally located

# CARCINOMA

Frequent invasion to neighboring organs - • Pleura, mediastinum.

Involvement of regional lymph nodes – • 50%.

Distant spread – lymphatic or hematogenic. •

Metastases as presenting symptoms – • frequent.

## Bronchogenic carcinoma

Frequent location of metastases: • Adrenals – more than 50% • Liver – 30-50% • Brain – 20% • Bone – 20% •

<b>Clinical vs histological classification</b>			
Squamous cell	Non small cell carcinoma		
carcinoma (M32%-F25%)			
<ul> <li>Adenocarcinoma</li> </ul>	Non squamous non small cell carcinoma (EGFR)		
(M37%-F47%)			
Large cell carcinoma			
(M18%-F10%)			
Small cell carcinoma			
(M14%-F18%)	Small cell carcinoma		

#### 10% - combined carcinoma

# **Precursor lesions**


- Squamous dysplasia and carcinoma in situ
- Atypical adenomatous hyperplasia
- Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia


A precursor condition does not always imply a cancer. Its transformation is rarely preconceived.

#### **DEVELOPMENT OF BRONCHIAL CARCINOMA**

- Area of cytological atypia
- Thickening of bronchial mucosa
- Warty excrescence and erosion
  - a. Fungating into bronchial lumen
  - b. Infiltration along peribronchial wall
  - c. Producing intraparenchymal mass

#### Development of squamous cell carcinoma






#### **Bronchogenic carcinoma**





# Peribronchial infiltration



#### Squamous cell carcinoma

Frequent P53 mutations

overexpressio 80%EGFRmutations are rare




90% central

IHC supporting P63 CK 5-6


Cigarette <u>smoking</u>

# Squamous cell carcinoma

Histopathological characteristics: Keratin formation. Marked intercellular bridges (desmosomes).



## Keratin pearls



Poorly differentiated squamous cell carcinoma

# Desmosomes

# Adenocarcinoma

- Usual Adenocarcinoma
- Bronchioloalveolar carcinoma

No link with smoking � Good prognosis �

#### Adenocarcinoma (Usual)



Mostly in women and non-smokers

Next to scar


mutations K-RAS EGFR

TTF1 NAPSIN A Supporting IHC


peripheral 75%

### **Usual Adenocarcinoma**

- ACINAR -
- PAPILLARY -
  - SOLID -
- Glandular differentiation or mucus formation. –




#### Mucous staining- (Mucicarmine) 80%Positive



### **Bronchioloalveolar carcinoma**

1-9% of lung cancers –
Nodular formation –
Or pneumonia-like consolidation. –
HISTOPATHOLOGY: –
Spreads along preserved alveoli (Lepidic) –
Composed of cuboidal or columnar cells. –





# Bronchioloalveolar carcinoma

- Non mucinous (adenocarcinoma in situ)
  - Columnar, peg shaped, cuboidal
  - Peripheral lung nodule

#### - Mucinous

- Tall columnar with cytoplasmatic and intra alveolar mucin
- Aerogenously spread forming satellite tumors
- May resemble lobar pneumonia






### Non-Small Cell Lung Cancer (NSCLC)

NSCLC differs from Small Cell Lung Cancer by a • variety of histomorphological features, by a diverse biological activity, and therefore, by a changing response to chemotherapy, to biological and to radiotherapy.

A standard NSCLC case, displaying metastases, a • positive expression for PD-L1, and no abnormal EGFR or ALK expression, may respond best to biological therapy with nivolumab, and with ipilimumab.

#### SMALL CELL LUNG CANCER (SCLC)

Small cell lung cancer is highly sensitive to
radiotherapy. However, this mode of
treatment is insufficient, due to the very
high stage of this malignancy at diagnosis.
Therefore, it is highly advised to
append treatment with EGFR tyrosine
kinase inhibitor, as well as with an
antiangiogenic mode of therapy.



#### Small cell carcinoma (poorly differentiated neuroendocrine carcinoma)

Microscopic features:

Small epithelial cells, scant cytoplasm, fine granular nuclear chromatin

High mitotic activity

Extensive necrosis

**Electron microscopic studies:** 


Dense-core neurosecretory granules in some of tumor cells <u>Molecular studies :</u>

Mutant expression: 80-100% RB, 50-80% p53

High levels of BCL-2 (anti apoptotic) - 90%

Reduction of BAX (proapoptotic gene) expression


# Small cell carcinoma



Azzopardi effect

# Large cell carinoma

Composed of large, undifferentiated, malignant cells. A neuroendocrine variant is described.



# **Bronchial Carcinoid**

No relation with smoking; good prognosis; mostly below age 40. May present as a button in the bronchial wall. **Classification:** Typical carcinoid (well differentiated


**Typical carcinoid** (well differeniated neuroendocrine carcinoma)

<u>Atypical carcinoid</u> (moderately differentiated neuroendocrine carcinoma)

# **Bronchial Carcinoid**

#### **MICROSCOPIC FEATURES:**

Organoid (growing organ-like). Surrounded by delicate connective tissue. Nests or cords, with uniform cells. Positive for neuroendocrine markers.




Neuroendocrine carcinoma	5y survival (%)	10y survival (%)
Typical Carcinoid	87	87
Atypical carcinoid	56	35
Large cell neuroendocrine carcinoma	27	9
Small cell carcinoma	9	5

# Pulmonary Hamartoma







# **Pulmonary Hamartoma**







# **Pleural Tumors**



#### MALIGNANT MESOTHELIOMA


## MALIGNANT MESOTHELIOMA

#### **Microscopic types:**

- Mesenchymal (20%) (sarcomatoid) spindle cells
- **Epithelioid (60%)** forming tubular and papillary structures
- Mixed (20%)

#### **E.M examination:**

• Long microvilli (gold standard)



## MALIGNANT MESOTHELIOMA

